|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIST1H2BC |
Gene summary for HIST1H2BC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIST1H2BC | Gene ID | 8347 |
| Gene name | H2B clustered histone 4 | |
| Gene Alias | H2B.1 | |
| Cytomap | 6p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0002227 | UniProtAcc | B2R4S9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8347 | HIST1H2BC | LZE4T | Human | Esophagus | ESCC | 6.27e-12 | 3.95e-01 | 0.0811 |
| 8347 | HIST1H2BC | LZE5T | Human | Esophagus | ESCC | 7.81e-07 | 6.18e-01 | 0.0514 |
| 8347 | HIST1H2BC | LZE7T | Human | Esophagus | ESCC | 5.55e-05 | 2.72e-01 | 0.0667 |
| 8347 | HIST1H2BC | LZE20T | Human | Esophagus | ESCC | 2.66e-23 | 1.10e+00 | 0.0662 |
| 8347 | HIST1H2BC | LZE21D1 | Human | Esophagus | HGIN | 2.45e-05 | 9.47e-01 | 0.0632 |
| 8347 | HIST1H2BC | LZE22D1 | Human | Esophagus | HGIN | 2.97e-02 | 1.32e-01 | 0.0595 |
| 8347 | HIST1H2BC | LZE22T | Human | Esophagus | ESCC | 7.10e-08 | 6.18e-01 | 0.068 |
| 8347 | HIST1H2BC | LZE24T | Human | Esophagus | ESCC | 3.22e-22 | 8.30e-01 | 0.0596 |
| 8347 | HIST1H2BC | LZE21T | Human | Esophagus | ESCC | 2.86e-08 | 6.45e-01 | 0.0655 |
| 8347 | HIST1H2BC | LZE6T | Human | Esophagus | ESCC | 4.04e-04 | 5.79e-01 | 0.0845 |
| 8347 | HIST1H2BC | P1T-E | Human | Esophagus | ESCC | 5.44e-19 | 8.14e-01 | 0.0875 |
| 8347 | HIST1H2BC | P2T-E | Human | Esophagus | ESCC | 1.80e-47 | 9.09e-01 | 0.1177 |
| 8347 | HIST1H2BC | P4T-E | Human | Esophagus | ESCC | 1.39e-12 | 4.15e-01 | 0.1323 |
| 8347 | HIST1H2BC | P8T-E | Human | Esophagus | ESCC | 4.24e-18 | 3.93e-01 | 0.0889 |
| 8347 | HIST1H2BC | P9T-E | Human | Esophagus | ESCC | 3.29e-16 | 8.68e-01 | 0.1131 |
| 8347 | HIST1H2BC | P10T-E | Human | Esophagus | ESCC | 3.18e-32 | 7.89e-01 | 0.116 |
| 8347 | HIST1H2BC | P12T-E | Human | Esophagus | ESCC | 1.64e-25 | 8.78e-01 | 0.1122 |
| 8347 | HIST1H2BC | P15T-E | Human | Esophagus | ESCC | 5.30e-27 | 8.22e-01 | 0.1149 |
| 8347 | HIST1H2BC | P16T-E | Human | Esophagus | ESCC | 1.31e-06 | 2.48e-01 | 0.1153 |
| 8347 | HIST1H2BC | P17T-E | Human | Esophagus | ESCC | 1.73e-12 | 1.03e+00 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIST1H2BC | SNV | Missense_Mutation | c.214G>C | p.Glu72Gln | p.E72Q | P62807 | protein_coding | deleterious_low_confidence(0.02) | benign(0.172) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
| HIST1H2BC | SNV | Missense_Mutation | c.161N>C | p.Gly54Ala | p.G54A | P62807 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.813) | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.340N>A | p.Glu114Lys | p.E114K | P62807 | protein_coding | tolerated_low_confidence(0.07) | benign(0.031) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.308N>C | p.Leu103Pro | p.L103P | P62807 | protein_coding | deleterious_low_confidence(0.01) | benign(0.43) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| HIST1H2BC | SNV | Missense_Mutation | c.259N>A | p.Arg87Ser | p.R87S | P62807 | protein_coding | deleterious_low_confidence(0.01) | benign(0.14) | TCGA-D8-A1XF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.374C>T | p.Ser125Phe | p.S125F | P62807 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.95) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.133N>C | p.Val45Leu | p.V45L | P62807 | protein_coding | deleterious_low_confidence(0.02) | benign(0.033) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.214N>C | p.Glu72Gln | p.E72Q | P62807 | protein_coding | deleterious_low_confidence(0.02) | benign(0.172) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| HIST1H2BC | SNV | Missense_Mutation | novel | c.108N>C | p.Glu36Asp | p.E36D | P62807 | protein_coding | deleterious_low_confidence(0.02) | benign(0.047) | TCGA-C5-A1BJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| HIST1H2BC | SNV | Missense_Mutation | c.222N>G | p.Ile74Met | p.I74M | P62807 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.957) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |